ACUMA Trademark

Trademark Overview


On Monday, May 17, 2021, a trademark application was filed for ACUMA with the United States Patent and Trademark Office. The USPTO has given the ACUMA trademark a serial number of 90715573. The federal status of this trademark filing is FIFTH EXTENSION - GRANTED as of Thursday, August 15, 2024. This trademark is owned by Teva Pharmaceuticals USA, Inc.. The ACUMA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of ...
acuma

General Information


Serial Number90715573
Word MarkACUMA
Filing DateMonday, May 17, 2021
Status734 - FIFTH EXTENSION - GRANTED
Status DateThursday, August 15, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 28, 2021

Trademark Statements


Goods and ServicesPharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical preparations, namely, contraceptive preparations; Pharmaceutical preparations, namely, fertility enhancement preparations; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical agents affecting the central nervous system; Pharmaceutical agents affecting circulatory systems; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents affecting urogenital organs; Pharmaceutical agents affecting peripheral nervous system
Translation of Words in MarkThe English translation of the word "ACUMA" in the mark is "now".

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSaturday, August 14, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameTeva Pharmaceuticals USA, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Party NameTeva Pharmaceuticals USA, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Trademark Events


Event DateEvent Description
Thursday, May 20, 2021NEW APPLICATION ENTERED
Friday, November 12, 2021ASSIGNED TO EXAMINER
Saturday, August 14, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, November 17, 2021NON-FINAL ACTION WRITTEN
Wednesday, November 17, 2021NON-FINAL ACTION E-MAILED
Wednesday, November 17, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, November 19, 2021EXAMINER'S AMENDMENT ENTERED
Friday, November 19, 2021EXAMINERS AMENDMENT -WRITTEN
Friday, November 19, 2021EXAMINERS AMENDMENT E-MAILED
Friday, November 19, 2021NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Friday, November 19, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, December 8, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 28, 2021PUBLISHED FOR OPPOSITION
Tuesday, December 28, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 22, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, July 7, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, July 7, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, July 7, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, July 26, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, July 26, 2022SOU EXTENSION 1 FILED
Tuesday, July 26, 2022SOU EXTENSION 1 GRANTED
Thursday, February 2, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, July 28, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, February 2, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, February 16, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, February 2, 2023TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Thursday, February 2, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, February 14, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, February 14, 2023SOU EXTENSION 2 FILED
Tuesday, February 14, 2023SOU EXTENSION 2 GRANTED
Friday, August 18, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, February 20, 2024SOU EXTENSION 4 FILED
Tuesday, February 20, 2024SOU EXTENSION 4 GRANTED
Tuesday, February 20, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, February 21, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, August 15, 2024SOU TEAS EXTENSION RECEIVED
Thursday, August 15, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, August 15, 2024SOU EXTENSION 5 FILED
Thursday, August 15, 2024SOU EXTENSION 5 GRANTED
Wednesday, August 16, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, August 16, 2023SOU EXTENSION 3 FILED
Wednesday, August 16, 2023SOU EXTENSION 3 GRANTED